Cite this: *Org. Biomol. Chem.*, 2016, **14**, 9093

Total synthesis of odoamide, a novel cyclic depsipeptide, from an Okinawan marine cyanobacterium†

Masato Kaneda,^a Kosuke Sueyoshi,^b Toshiaki Teruya,^b Hiroaki Ohno,^a Nobutaka Fujii^a and Shinya Oishi^{*a}

Odoamide is a novel cyclic depsipeptide with highly potent cytotoxic activity isolated from the Okinawan marine cyanobacterium *Okeania* sp. It contains a 26-membered macrocycle composed of a fatty acid moiety, a peptide segment and isoleucic acid. Four possible stereoisomers of the odoamide polyketide substructure were synthesised using a chiral pool approach. The first total synthesis of odoamide was also successfully achieved. The structure of synthetic odoamide was verified by comparing its NMR spectra with those of the natural product.

Received 25th July 2016,
Accepted 1st September 2016

DOI: 10.1039/c6ob01583b

www.rsc.org/obc

Introduction

Many peptide secondary metabolites derived from natural resources show attractive biological activities.¹ Because of their favourable drug-like properties including good membrane permeability and biostability,² a number of synthetic and medicinal chemistry studies of macrocyclic peptides and highly *N*-methylated peptides have been carried out.³ Among them, autilide-class cyclic depsipeptides exhibit highly potent antiproliferative activity against cancer cell lines (Fig. 1). The first 26-membered cyclic depsipeptide, autilide (**1a**), was isolated from the sea hare *Dolabella auricularia*.⁴ The related depsipeptides, autilide B (**1b**) and C (**1c**), from *Lyngbya majuscula* also show potent cytotoxicity.⁵ Kulokekahlide-2 (**2**) is a similar cytotoxic depsipeptide from a marine mollusk, *Philineopsis speciosa*, which has two conformers of the 26-membered macrocycle in dichloromethane.⁶ Lagunamide A (**3a**) and B (**3b**) from *Lyngbya majuscula* exhibit antimalarial activity against *Plasmodium falciparum* at submicromolar concentrations.⁷ Lagunamide C (**3c**)⁸ and palau'amide (**4**)⁹ exhibit cytotoxicity at nanomolar concentrations comparable to other autilide-class depsipeptides, although these peptides have unique 27-membered and 24-membered macrocycles,

respectively. The configurations of the component amino acids of the depsipeptides were investigated by chiral HPLC, chiral GC-MS, and Marfey's analyses,¹⁰ while the stereo-selective synthesis and the NMR analysis facilitated the determination of the absolute stereochemistries of the fatty acid substructure. In some cases, the structure was verified or revised through synthetic studies of natural products and their stereoisomers.¹¹

Odoamide (**5**) is a novel cyclic depsipeptide from the Okinawan marine cyanobacterium *Okeania* sp. (Fig. 2A), which shows highly potent cytotoxic activity against HeLa S₃ cell lines.¹² The overall structure of the 26-membered macrocycle is similar to those of autilide-class depsipeptides, and comprises three substructures: a fatty acid moiety, a peptide segment (Ala-D-MePhe-Sar-Ile-MeAla) and isoleucic acid. At the initial stage of this study, the absolute configurations of the constituent amino acids and isoleucic acid in **5** were determined by chiral HPLC analysis and Marfey's analysis. The absolute configuration of the 5-hydroxy group of the polyketide part was determined by Mosher's method,¹³ while the remaining configurations of the polyketide were ambiguous. In this study, we carried out a synthetic study of odoamide to verify its structure and complete stereochemistry.

The synthetic strategy is illustrated in Scheme 1. During the cyclisation of the linear peptide, epimerisation and dimer formation are often problematic.^{3e,f,14} To avoid the less reactive process of *N*-methylated amide (CO-NMe) or ester bond formation compared with standard peptide bond (CO-NH) formation, we chose macrocyclisation of the Ala and D-allo-isoleucic acid residues of the linear precursor **6** for odoamide (**5**).^{11d} Peptide **6** could be prepared by coupling of alcohol **7**,

^aGraduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan. E-mail: soishi@pharm.kyoto-u.ac.jp; Fax: +81-75-753-4570; Tel: +81-75-753-4561

^bFaculty of Education, University of the Ryukyus, Nishihara, Okinawa 903-0213, Japan

†Electronic supplementary information (ESI) available. See DOI: 10.1039/c6ob01583b

Fig. 1 Structures of aurilide-class depsipeptides.

MeAla 8 and tetrapeptide 9, which could be obtained by standard solid-phase peptide synthesis. Alcohol 7 could be synthesised by coupling of *D*-*allo*-isoleucic acid ester 11¹⁵ with carboxylic acid 10.

Results and discussion

Synthesis of the polyketide substructure of odoamide

The stereochemistries of the polyketide part were unknown when we started this study. Therefore, it was necessary to synthesise all the possible polyketide substructures of odoamide 5. The polyketide substructure in lagunamide A (3a), a closely related structural analogue of 5, has 5*S*,7*R*-dihydroxy and 6*S*,8*S*-dimethyl groups. Additionally, aurilide-class depsipeptides 1a–c, 2, and 3a,b possess the *syn*-1,3-diol moiety with a 5*S*-hydroxy configuration. On the basis of the structures of these related molecules, we expected that the plausible stereochemical configuration of the natural odoamide 5 was 5*S*,6*S*,7*R*,8*S*. Among these four stereocentres, the configuration at the C8-methyl group was ambiguous because attempts to determine it based on derivatisation and NMR analysis of odoamide (5) were unsuccessful. It was also desirable to

confirm the stereochemistry of the C6-methyl group. Therefore, we designed four possible methyl esters 12a–d as polyketide substructure substrates (Fig. 2B).

Methyl esters 12a,b were synthesised from (*S*)-Roche ester 13 according to a similar process described in previous reports by us and others (see the ESI†).^{11a,12} Preparation of (5*S*,6*R*,7*R*,8*S*)-ester 12c and (5*S*,6*R*,7*R*,8*R*)-ester 12d started from the commercially available (*R*)-Roche ester *ent*-13 in a similar manner (Scheme 2). (*R*)-Roche ester *ent*-13 was converted to alcohol *ent*-15 via benzyl protection¹⁶ and LiAlH₄-mediated reduction. After Swern oxidation, an *n*-Bu₂BOTf-mediated Evans aldol reaction¹⁷ of the resulting aldehyde provided the *syn*-aldol products 16c and 17d. The requisite stereochemistries at the C8 chiral centre in 12c and 12d were generated at this step by using propionyl- and pentanoyl-oxazolidinones, respectively. TBS protection of the secondary alcohol in 16c and 17d followed by removal of the chiral auxiliary with LiBH₄ gave alcohols 20c¹⁸ and 21d. Swern oxidation of 20c and the subsequent Wittig reaction of the resulting aldehyde with ethylidene-triphenylphosphorane provided olefin 22c as an *E/Z* isomeric mixture. Hydrogenation of 22c in the presence of Pd/C afforded the key alcohol 23c with a *threo*/*threo*-configuration. Separately, tosylation of 21d followed by

Fig. 2 Structures of odoamide (5) (A) and the polyketide substructures in 5 (B).

LiAlH₄-mediated reduction afforded benzyl ether **24d**, which was converted to the corresponding alcohol **23d** (with a *threo*/*erythro*-configuration) by hydrogenation. Swern oxidation of **23c** followed by a Mukaiyama aldol reaction¹⁹ with 1-methoxy-2-methyl-1-trimethylsiloxy-1,3-butadiene (**25**)²⁰ produced methyl ester **12c** with a (5*S*)-hydroxy group (dr >99 : 1).²¹ Ester **12d** was obtained from **23d** by using the identical protocol.

The stereochemistry of the 5-hydroxy group in alcohol **12a** was confirmed by the NMR analysis of the corresponding acetone (Scheme 3). TBS deprotection of **26a**²² and **12a** provided 1,3-diols **27a** and **28a**, which were treated with 2,2-dimethoxypropane in the presence of PPTS to give acetones **29a** and **30a**, respectively. It is known that ¹³C NMR chemical shifts of the ketal methyl groups in *syn*- and *anti*-1,3-diol acetones are different.²³ A *syn*-acetone shows different chemical shifts for the two ketal methyl groups (*e.g.*, 19.5 and 30.0 ppm for **30a**) because of its predominant chair conformation. In contrast, an *anti*-acetone shows close chemical shifts (*e.g.*, 23.5 and 25.2 ppm for **29a**), because the *anti*-isomer exists in a twist-boat conformation to avoid the 1,3-diaxial interaction that would be present in the chair conformation. Accordingly, it was demonstrated that 1,3-diol **28a**,

Scheme 1 Retrosynthetic analysis of odoamide (5).

the precursor of acetone **30a** has the desired 1,3-*syn* configuration. Of note, esters **12a–d** were employed as the key substrates for the stereochemical assignment of the polyketide substructure in **5** in our previous research.¹² Manipulations of esters **12a–d** including DIBAL-mediated reductive transformation provided the corresponding triol derivatives. The comparative NMR analysis between the natural product-derived triol and synthetic triols demonstrated that the polyketide substructure had the 5*S*,6*S*,7*R*,8*S* configuration (see the ESI†).¹²

Synthesis of odoamide and its biological evaluation

After the determination of the stereochemistry of the polyketide part,¹² we attempted the total synthesis of odoamide

Scheme 2 Synthesis of esters **12c,d**. Reagents and conditions: (a) benzyl 2,2,2-trichloroacetimidate, TfOH, CH₂Cl₂, cyclohexane, 0 °C to rt, 85%; (b) LiAlH₄, THF, 0 °C, 81%; (c) (COCl)₂, DMSO, DIPEA, CH₂Cl₂, –78 °C to 0 °C; (d) (R)-4-benzyl-3-propionyl-2-oxazolidinone, *n*-Bu₂BOTf, DIPEA, CH₂Cl₂, –78 °C to –10 °C, 80% (2 steps); (e) (R)-4-benzyl-3-pentanoyl-2-oxazolidinone, *n*-Bu₂BOTf, DIPEA, CH₂Cl₂, –78 °C to –10 °C, 72% (2 steps); (f) TBSOTf, 2,6-lutidine, CH₂Cl₂, 0 °C to rt, 89% (**18c**) and 87% (**19d**); (g) LiBH₄, MeOH, THF, 0 °C to rt, 69% (**20c**) and 80% (**21d**); (h) (COCl)₂, DMSO, DIPEA, CH₂Cl₂, –78 °C to 0 °C; (i) ethyltriphenylphosphonium bromide, *n*-BuLi, THF, rt, 69% (2 steps, *Z/E* = 7 : 1); (j) TsCl, Et₃N, Me₃N·HCl, CH₂Cl₂, rt; (k) LiAlH₄, THF, 0 °C to rt, 70% (2 steps) (l) Pd/C, H₂, EtOH, rt, 92% (**23c**) and 85% (**23d**); (m) (COCl)₂, DMSO, DIPEA, CH₂Cl₂, –78 °C to 0 °C; (n) **25**, BF₃·OEt₂, CH₂Cl₂, Et₂O, –78 °C, 54% (**12c**) and 69% (**12d**) (2 steps).

Scheme 3 Stereochemical assignment of 1,3-diols. Reagents and conditions: (a) TBAF, THF, rt, 81% (**27a**) and 81% (**28a**); (b) 2,2-dimethoxypropane, PPTS, CH₂Cl₂, rt, 86% (**29a**) and 90% (**30a**).

using (5*S*,6*S*,7*R*,8*S*)-ester **12a**. Synthesis of odoamide (**5**) began with methylthiomethyl (MTM) protection of the secondary hydroxy group in **12a** to give thioacetal **31**

(Scheme 4).^{11a,24} Hydrolysis of **31** with LiOH followed by coupling with *D*-*allo*-isoleucic acid phenacyl ester (**11**) using 2-methyl-6-nitrobenzoic anhydride (MNBA)²⁵ and DMAP afforded ester **32**. The TBS group in **32** was deprotected with HF·pyridine to produce the corresponding alcohol **7**. In the coupling of Fmoc-MeAla-OH **8** with **7** using DCC and DMAP, significant epimerisation occurred. The coupling using Fmoc-MeAla-Cl²⁶ with **7** in the presence of DIPEA followed by Fmoc deprotection with Et₃NH gave amine **33** in 54% yield (two steps) without epimerisation. Tetrapeptide **9** was conjugated with **33** using EDCI-HOAt to afford **34** as a 1.4 : 1 epimeric mixture at the α-position of Ile.²⁷ After removal of the phenacyl (with Zn and AcOH) and Fmoc groups (with Et₃NH), the epimer mixture of the linear peptides was separated into the desired compound **6a** (major, *L*-Ile) and undesired compound **6b** (minor, *D*-*allo*-Ile) by HPLC purification. Cyclisation of **6a** and **6b** with HATU followed by deprotection of the MTM group with AgNO₃ and 2,6-lutidine gave the desired odoamide **5a** and its diastereomer **5b**. Both cyclisations of **6a** and **6b** proceeded smoothly within five hours without epimerisation. The configurations of *L*-Ile and *D*-*allo*-Ile in peptides **5a** and **5b**, respectively, were determined by Marfey's analysis and ¹H NMR analysis after acid hydrolysis.

We analysed the ¹H NMR and ¹³C NMR spectra of the natural and synthetic products (Fig. 3 and 4). The NMR spectra of the synthetic odoamide **5a** were identical to those of the

Scheme 4 Synthesis of odoamide (**5a**) and its epimer **5b**. Reagents and conditions: (a) Ac_2O , DMSO, AcOH , rt, 59%; (b) LiOH , THF, MeOH, H_2O , 0 °C to 30 °C; (c) **11**, MNBA, DMAP, CH_2Cl_2 , rt, 87% (2 steps); (d) HF-pyridine, THF, pyridine, 0 °C to rt, 74%; (e) Fmoc-MeAla-Cl, DIPEA, 1,2-dichloroethane, 40 °C; (f) Et_2NH , MeCN, 0 °C to rt, 54% (2 steps); (g) **9**, EDCI-HCl, HOAt, CH_2Cl_2 , 0 °C to rt; (h) Zn, CH_3COOH , H_2O , EtOAc, rt; (i) Et_2NH , MeCN, 0 °C to rt, 30% (**6a**) and 24% (**6b**) (3 steps); (j) HATU, HOAt, collidine, DMF, rt; (k) AgNO_3 , 2,6-lutidine, THF, H_2O , rt to 70 °C, 85% (**5a**) and 62% (**5b**) (2 steps).

natural product **5**, suggesting that the chemical structure of odoamide was the same as **5a**. The cytotoxicity of synthetic odoamides **5a** and **5b** against A549 cells was also evaluated by the MTS assay. Peptide **5a** showed highly potent cytotoxicity ($\text{IC}_{50} = 2.1 \text{ nM}$), corroborating our correct structural assignment of odoamide (**5**). However, the epimer peptide **5b** showed significantly less potent antiproliferative activity ($\text{IC}_{50} = 0.54 \text{ }\mu\text{M}$), suggesting that the L-Ile configuration is crucial for the cytotoxic activity of odoamide.

Conclusions

In this study, the total synthesis of odoamide was completed via the synthesis of four possible polyketide substructures **12a–d**. The NMR spectra of the synthetic peptide **5a** were identical to those of the natural odoamide **5**. Accordingly, the full structural assignment and first total synthesis of odoamide were achieved.

Fig. 3 Comparison of the ¹H NMR spectra between the natural compound 5 and the synthetic compound 5a (in CD₃OD).

Fig. 4 Comparison of the ¹³C NMR spectra between the natural compound 5 and the synthetic compound 5a (in CD₃OD).

Experimental section

Synthetic general method

NMR spectra were recorded using a JEOL ECA-500 spectrometer. Chemical shifts are reported in δ (ppm) relative to Me₄Si (in CDCl₃) as an internal standard. ¹³C NMR spectra were referenced to the residual solvent signal. Melting points were measured by a hot stage melting point apparatus (uncorrected). Exact mass (HRMS) spectra were recorded on a Shimadzu LC-ESI-IT-TOF-MS instrument. IR spectra were recorded on a JASCO FT/IR-4100 spectrometer. Optical rotations were measured with a JASCO P-1020 polarimeter. For flash chromatography, Wakogel C-300E (Wako) was employed. For analytical HPLC, a Cosmosil 5C18-ARII column (4.6 × 250 mm, Nacalai Tesque, Inc.) was employed with a linear gradient of CH₃CN (with 0.1% (v/v) TFA, except for the analysis of final products **5a,b** using solvents without TFA) in H₂O at a flow rate of 1 cm³ min^{−1}, and eluting products were detected by UV at 220 nm. Preparative HPLC was performed using a Cosmosil 5C18-ARII preparative column (20 × 250 mm, Nacalai Tesque, Inc.) at a flow rate of 8 cm³ min^{−1}. The purity of peptides **5a,b** was determined by HPLC analysis (>95%). The synthetic procedures for esters **12a,b** were described in our previous report.¹²

Methyl (R)-3-benzyloxy-2-methylpropanoate (ent-14). To a stirred solution of *ent*-**13** (9.9 g, 83.8 mmol) in CH₂Cl₂ (210 cm³) under argon were added benzyl 2,2,2-trichloroacetimidate (17.1 cm³, 92.2 mmol) in cyclohexane (420 cm³) and triflic acid (3.0 cm³, 33.5 mmol) at 0 °C. After 10 min, the reaction mixture was warmed to room temperature and stirred for 18 h. The precipitated trichloroacetamide was filtered off. The filtrate was washed with saturated aqueous NaHCO₃ and brine, and dried over MgSO₄. The filtrate was concentrated under reduced pressure and the residue was purified by flash chromatography over silica gel with hexane–EtOAc (50 : 1 to 10 : 1) to give compound *ent*-**14** (14.8 g, 85%) as a colorless oil. The spectral data were in good agreement with those previously reported.²⁸

(S)-3-Benzyloxy-2-methylpropan-1-ol (ent-15). To a stirred suspension of LiAlH₄ (4.0 g, 105.9 mmol) in THF (175 cm³) under argon was added dropwise a solution of *ent*-**14** (14.7 g, 70.6 mmol) in THF (175 cm³) at 0 °C. After stirring for 1 h, the reaction mixture was poured into a saturated aqueous solution of sodium potassium tartrate at 0 °C and stirred overnight at room temperature. The whole mixture was extracted with Et₂O and the extract was washed with brine, and dried over MgSO₄. The filtrate was concentrated under reduced pressure and the residue was purified by flash chromatography over silica gel with hexane–EtOAc (9 : 1 to 3 : 1) to give compound *ent*-**15** (10.3 g, 81%) as a colorless oil. The spectral data were in good agreement with those previously reported.²⁸

(R)-4-Benzyl-3-[(2R,3S,4R)-5-benzyloxy-3-hydroxy-2,4-dimethylpentanoyl]oxazolidin-2-one (16c). To a stirred solution of oxalyl chloride (0.32 cm³, 3.72 mmol) in CH₂Cl₂ (7.4 cm³) under argon was added DMSO (0.53 cm³, 7.44 mmol) in CH₂Cl₂ (1.2 cm³) at −78 °C. After stirring for 30 min, a solution

of *ent*-**15** (334.7 mg, 1.86 mmol) in CH₂Cl₂ (6.4 cm³) was added dropwise and stirred at −78 °C for 1 h. *i*-Pr₂NEt (1.62 cm³, 9.3 mmol) was added and the reaction mixture was stirred at 0 °C for 30 min. The mixture was quenched with saturated aqueous NH₄Cl. The whole mixture was extracted with CH₂Cl₂ and the extract was washed with brine, and dried over MgSO₄. The filtrate was concentrated under reduced pressure to give the corresponding aldehyde, which was used without further purification.

To a stirred solution of (*R*)-4-benzyl-3-propionyloxazolidin-2-one (429.2 mg, 1.84 mmol) in CH₂Cl₂ (9.2 cm³) under argon were added *n*-Bu₂BOTf (1.0 mol dm^{−3} in CH₂Cl₂; 2.0 cm³, 2.00 mmol) and *i*-Pr₂NEt (0.38 cm³, 2.17 mmol) at −78 °C. After stirring for 1 h, the reaction mixture was warmed to 0 °C and stirred for 30 min. To this solution was added the above aldehyde in CH₂Cl₂ (3.9 cm³) at −78 °C. After stirring for 1 h, the mixture was warmed to −10 °C and stirred for 1 h. The mixture was quenched with pH 7.0 phosphate buffer solution (1.8 cm³) and 30% H₂O₂ in MeOH (1 : 2, 4.2 cm³) and stirred overnight at room temperature. The whole mixture was concentrated under reduced pressure and extracted with CH₂Cl₂. The extract was washed with saturated aqueous NaHCO₃, and dried over MgSO₄. The filtrate was concentrated under reduced pressure and the residue was purified by flash chromatography over silica gel with hexane–EtOAc (5 : 1 to 3 : 1) to give compound **16c** (610.7 mg, 80%, dr >15 : 1) as a colorless oil. The minor isomer was removed by column chromatography: [α]_D²⁹ −43.2 (*c* 0.72, CHCl₃); IR (neat) $\nu_{\max}$ /cm^{−1}: 3504 (OH), 1779 (C=O); ¹H NMR (500 MHz, CDCl₃) δ : 1.05 (3H, d, *J* 6.9), 1.33 (3H, d, *J* 6.3), 1.87–1.93 (1H, m), 2.77 (1H, dd, *J*₁ 13.2, *J*₂ 9.7), 3.00 (1H, d, *J* 2.9), 3.25 (1H, dd, *J*₁ 13.2, *J*₂ 3.2), 3.46–3.52 (2H, m), 3.96–4.03 (2H, m), 4.16–4.21 (2H, m), 4.51 (2H, s), 4.65–4.69 (1H, m), 7.20–7.21 (2H, m), 7.26–7.36 (8H, m); ¹³C NMR (125 MHz, CDCl₃) δ : 12.4, 12.8, 36.2, 37.7, 40.5, 55.1, 66.0, 73.3, 73.9, 74.1, 127.4 (2C), 127.5 (2C), 128.3 (2C), 128.9 (2C), 129.4 (2C), 135.0, 138.1, 152.7, 177.0; HRMS (ESI) calcd for C₂₄H₂₉NNaO₅ (MNa⁺): 434.1938; found: 434.1938.

(R)-4-Benzyl-3-[(2R,3S,4R)-5-benzyloxy-3-(*tert*-butyldimethylsilyloxy)-2,4-dimethylpentanoyl]oxazolidin-2-one (18c). To a stirred solution of **16c** (14.1 g, 34.3 mmol) in CH₂Cl₂ (137 cm³) under argon were added TBSOTf (9.5 cm³, 41.2 mmol) and 2,6-lutidine (7.9 cm³, 68.6 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 2.5 h. The reaction was quenched with 1 N HCl. The whole mixture was extracted with CH₂Cl₂ and the extract was washed with brine, and dried over MgSO₄. The filtrate was concentrated under reduced pressure and the residue was purified by flash chromatography over silica gel with hexane–EtOAc (9 : 1) to give compound **18c** (16.0 g, 89%) as a colorless oil: [α]_D²⁷ −38.2 (*c* 1.21, CHCl₃); IR (neat) $\nu_{\max}$ /cm^{−1}: 1780 (C=O); ¹H NMR (500 MHz, CDCl₃) δ : 0.04 (3H, s), 0.06 (3H, s), 0.90 (9H, s), 0.92 (3H, d, *J* 7.4), 1.25 (3H, d, *J* 6.9), 1.88–1.93 (1H, m), 2.75 (1H, dd, *J*₁ 13.2, *J*₂ 9.7), 3.24 (1H, dd, *J*₁ 13.2, *J*₂ 3.2), 3.28 (1H, dd, *J*₁ 8.9, *J*₂ 7.2), 3.49 (1H, dd, *J*₁ 8.9, *J*₂ 6.6), 3.96–4.02 (1H, m), 4.08–4.16 (3H, m), 4.46–4.52 (2H, m), 4.59–4.64 (1H, m), 7.20–7.34 (10H, m); ¹³C NMR (125 MHz, CDCl₃) δ : −4.1, −3.9,

11.9, 15.0, 18.4, 26.1 (3C), 37.6, 38.8, 41.9, 55.4, 65.9, 72.8, 73.0, 73.4, 127.3, 127.4, 127.6 (2C), 128.3 (2C), 128.9 (2C), 129.4 (2C), 135.3, 138.6, 152.8, 175.9; HRMS (ESI) calcd for $C_{30}H_{43}NNaO_5Si$ (MNa^+): 548.2803; found: 548.2808.

(2S,3R,4R)-5-Benzyloxy-3-(tert-butyldimethylsilyloxy)-2,4-dimethylpentan-1-ol (20c). To a stirred solution of **18c** (22.4 g, 42.5 mmol) in THF (213 cm³) and MeOH (5.2 cm³, 127.6 mmol) under argon was added LiBH₄ (2.78 g, 127.6 mmol) at 0 °C. After stirring for 10 min, the reaction mixture was warmed to room temperature. After 4 h, the mixture was cooled to 0 °C and quenched with saturated aqueous NH₄Cl. The whole mixture was extracted with EtOAc and the extract was washed with brine, and dried over MgSO₄. The filtrate was concentrated under reduced pressure and the residue was purified by flash chromatography over silica gel with hexane–EtOAc (9 : 1) to give compound **20c** (10.3 g, 69%) as a colorless oil: $[\alpha]_D^{29}$ –0.41 (c 1.23, CHCl₃); IR (neat) ν_{max}/cm^{-1} : 3422 (OH); ¹H NMR (500 MHz, CDCl₃) δ : 0.03 (3H, s), 0.08 (3H, s), 0.85 (3H, d, *J* 7.4), 0.89 (9H, s), 0.96 (3H, d, *J* 6.9), 1.93–1.98 (1H, m), 1.99–2.05 (1H, m), 2.32 (1H, br s), 3.26 (1H, dd, *J*₁ 9.2, *J*₂ 6.3), 3.39 (1H, dd, *J*₁ 9.2, *J*₂ 7.2), 3.47–3.51 (1H, m), 3.64–3.68 (1H, m), 3.88–3.89 (1H, m), 4.46–4.51 (2H, m), 7.26–7.36 (5H, m); ¹³C NMR (125 MHz, CDCl₃) δ : –4.5, –4.2, 12.8, 12.9, 18.2, 26.0 (3C), 35.9, 40.1, 66.3, 72.9, 73.6, 74.4, 127.5 (3C), 128.3 (2C), 138.5; HRMS (ESI) calcd for $C_{20}H_{36}NaO_3Si$ (MNa^+): 375.2326; found: 375.2324.

{[(2R,3R,4S)-1-(Benzyloxy)-2,4-dimethylhept-5-en-3-yl]oxy}(tert-butyl)dimethylsilane (22c). To a stirred solution of oxalyl chloride (0.11 cm³, 1.30 mmol) in CH₂Cl₂ (6.5 cm³) under argon was added DMSO (0.18 cm³, 2.60 mmol) in CH₂Cl₂ (0.43 cm³) at –78 °C. After stirring for 30 min, a solution of **20c** (228.9 mg, 0.65 mmol) in CH₂Cl₂ (2.2 cm³) was added dropwise and stirred at –78 °C for 1.5 h. *i*-Pr₂NEt (0.57 cm³, 3.25 mmol) was added and the reaction mixture was stirred at 0 °C for 30 min. The mixture was quenched with saturated aqueous NH₄Cl. The whole mixture was extracted with CH₂Cl₂ and the extract was washed with brine, and dried over MgSO₄. The filtrate was concentrated under reduced pressure to give the corresponding aldehyde, which was used without further purification. To a stirred suspension of ethyltriphenylphosphonium bromide (508.6 mg, 1.37 mmol) in THF (5.5 cm³) under argon was added *n*-BuLi (1.6 mol dm^{–3} in hexane; 0.81 cm³, 1.30 mmol) at room temperature. After stirring for 30 min, a solution of the above aldehyde in THF (1.3 cm³) was added and the reaction mixture was stirred for 1.5 h. The mixture was quenched with saturated aqueous NaHCO₃. The whole mixture was extracted with EtOAc and the extract was washed with brine, and dried over MgSO₄. The filtrate was concentrated under reduced pressure and the residue was filtered through a short pad of silica gel with hexane–EtOAc (9 : 1). Further purification by flash chromatography over silica gel with hexane–CHCl₃ (8 : 1) gave compound **22c** as a diastereomixture (163.7 mg, 69%, *Z/E* = 7 : 1): colorless oil; $[\alpha]_D^{27}$ +12.5 (c 1.17, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 0.01 (0.4H, s), 0.02 (2.6H, s), 0.04 (0.4H, s), 0.05 (2.6H, s), 0.84–0.86 (3H, m), 0.89 (1.2H, s), 0.90 (7.8H, s), 0.94–0.97 (3H, m), 1.61 (2.6H, dd,

*J*₁ 6.9, *J*₂ 1.7), 1.63 (0.4H, d, *J* 4.6), 1.96–2.03 (1H, m), 2.23–2.30 (0.1H, m), 2.60–2.65 (0.9H, m), 3.22 (1H, dd, *J*₁ 8.9, *J*₂ 6.9), 3.40 (1H, dd, *J*₁ 8.9, *J*₂ 7.7), 3.56 (1H, dd, *J*₁ 8.0, *J*₂ 1.7), 4.43–4.52 (2H, m), 5.16–5.21 (1H, m), 5.35–5.42 (1H, m), 7.25–7.34 (5H, m); ¹³C NMR (125 MHz, CDCl₃) δ : –4.1, –4.0, –3.6, –3.5, 10.8, 11.1, 13.0, 17.6, 18.1, 18.3, 18.4, 18.5, 26.2 (6C), 35.9, 36.6, 37.1, 41.5, 72.7, 72.8, 73.6, 73.9, 76.0, 76.2, 122.7, 123.8, 127.4, 127.5 (2C), 128.3 (2C), 134.5, 134.9, 138.7; HRMS (ESI) calcd for $C_{22}H_{38}NaO_2Si$ (MNa^+): 385.2533; found: 385.2534.

(2R,3R,4S)-3-(tert-Butyldimethylsilyloxy)-2,4-dimethylheptan-1-ol (23c). To a stirred solution of **22c** (1.3 g, 3.7 mmol) in EtOH (37.0 cm³) was added 10% Pd/C (787.5 mg, 0.7 mmol) at room temperature and the mixture was treated with H₂ gas (1 atm). After stirring for 1 h, the reaction mixture was filtered through Celite. The filtrate was concentrated under reduced pressure and the residue was purified by flash chromatography over silica gel with hexane–EtOAc (10 : 1) to give compound **23c** (938.1 mg, 92%) as a colorless oil: $[\alpha]_D^{28}$ –12.7 (c 1.13, CHCl₃); IR (neat) ν_{max}/cm^{-1} : 3328 (OH); ¹H NMR (500 MHz, CDCl₃) δ : 0.06 (3H, s), 0.08 (3H, s), 0.85 (3H, d, *J* 6.9), 0.88–0.92 (15H, m), 1.09–1.16 (1H, m), 1.19–1.28 (1H, m), 1.31–1.41 (2H, m), 1.60–1.66 (1H, m), 1.90–1.97 (1H, m), 2.07 (1H, dd, *J*₁ 6.0, *J*₂ 4.3), 3.45–3.50 (1H, m), 3.62–3.67 (2H, m); ¹³C NMR (125 MHz, CDCl₃) δ : –4.2, –4.1, 12.6, 14.3, 15.8, 18.3, 20.8, 26.0 (3C), 35.9, 37.0, 39.5, 66.5, 77.4; HRMS (ESI) calcd for $C_{15}H_{34}NaO_2Si$ (MNa^+): 297.2220; found: 297.2221.

Methyl (5S,6R,7R,8S,E)-7-(tert-butyldimethylsilyloxy)-5-hydroxy-2,6,8-trimethylundec-2-enoate (12c). To a stirred solution of *i*-Pr₂NH (0.16 cm³, 1.16 mmol) in THF (2.4 cm³) under argon was added *n*-BuLi (2.6 mol dm^{–3} in hexane; 0.45 cm³, 1.16 mmol) at 0 °C. After 20 min, methyl tiglate (0.13 cm³, 1.05 mmol) and TMSCl (0.20 cm³, 1.58 mmol) in THF (0.36 cm³) were added successively at –78 °C. The stirring was continued for 1 h at this temperature and for additional 1.5 h at room temperature. Then, pentane and cold saturated NaHCO₃ were added to the reaction mixture. The whole mixture was extracted with pentane and the extract was washed with brine, and dried over MgSO₄. The filtrate was concentrated under reduced pressure to give compound **25**, which was used without further purification.²⁰ To a stirred solution of oxalyl chloride (0.060 cm³, 0.70 mmol) in CH₂Cl₂ (3.5 cm³) under argon was added DMSO (0.099 cm³, 1.40 mmol) in CH₂Cl₂ (0.23 cm³) at –78 °C. After stirring for 30 min, a solution of **23c** (96.4 mg, 0.35 mmol) in CH₂Cl₂ (1.2 cm³) was added dropwise and stirred at –78 °C for 1.5 h. *i*-Pr₂NEt (0.49 cm³, 2.8 mmol) was added and the reaction mixture was stirred at 0 °C for 30 min. The mixture was quenched with saturated aqueous NH₄Cl. The whole mixture was extracted with CH₂Cl₂ and the extract was washed with brine, and dried over MgSO₄. The filtrate was concentrated under reduced pressure to give the corresponding aldehyde, which was used without further purification. To a stirred solution of the above aldehyde in CH₂Cl₂ (2.7 cm³) and Et₂O (0.27 cm³) under argon were added diene **25** and BF₃·OEt₂ (0.065 cm³, 0.53 mmol) at –78 °C. After stirring for 2 h, a mixture of THF/H₂O/1 N HCl (5 : 1 : 0.4 v/v, 1.8 cm³) was added to the reaction mixture. The

mixture was warmed to room temperature and stirred for 15 min. Then, saturated aqueous NaHCO₃ was added to the mixture at 0 °C. The whole mixture was extracted with CH₂Cl₂ and the extract was washed with brine, and dried over MgSO₄. The filtrate was concentrated under reduced pressure and the residue was purified by flash chromatography over silica gel with hexane–EtOAc (20 : 1 to 10 : 1) to give compound **12c** (73.4 mg, 54%) as a colorless oil: $[\alpha]_D^{26}$ –22.4 (*c* 1.01, CHCl₃); IR (neat) $\nu_{\max}/\text{cm}^{-1}$: 3523 (OH), 1716 (C=O); ¹H NMR (500 MHz, CDCl₃) δ : 0.08 (3H, s), 0.09 (3H, s), 0.85 (3H, d, *J* 6.9), 0.88–0.91 (12H, m), 0.94 (3H, d, *J* 6.9), 1.04–1.11 (1H, m), 1.15–1.22 (1H, m), 1.35–1.42 (1H, m), 1.46–1.53 (1H, m), 1.63–1.69 (2H, m), 1.87 (3H, s), 1.96 (1H, d, *J* 4.0), 2.31–2.42 (2H, m), 3.65–3.66 (1H, m), 3.74 (3H, s), 3.79–3.83 (1H, m), 6.79–6.82 (1H, m); ¹³C NMR (125 MHz, CDCl₃) δ : –4.2, –3.5, 8.9, 12.7, 14.4, 15.4, 18.3, 21.1, 26.0 (3C), 34.7, 35.3, 37.9, 40.1, 51.7, 73.7, 78.8, 129.3, 138.8, 168.4; HRMS (ESI) calcd for C₂₁H₄₂NaO₄Si (MNa⁺): 409.2745; found: 409.2748.

[[[(2R,3R,4R)-1-(Benzyloxy)-2,4-dimethylheptan-3-yl]oxy}(tert-butyl)dimethylsilane (24d). To a stirred solution of **21d** (7.3 g, 19.1 mmol) in CH₂Cl₂ (191 cm³) under argon were added Et₃N (5.3 cm³, 38.2 mmol), TsCl (5.5 g, 28.7 mmol) and Me₃N·HCl (1.8 g, 19.1 mmol) at room temperature. After stirring for 1 h, the reaction was quenched with saturated aqueous NH₄Cl. The whole mixture was extracted with CH₂Cl₂ and the extract was washed with brine, and dried over MgSO₄. The filtrate was concentrated under reduced pressure and the precipitated white solid was filtered off. The filtrate was concentrated under reduced pressure to give the corresponding tosylate, which was used without further purification. To a stirred suspension of LiAlH₄ (2.2 g, 57.3 mmol) in THF (100 cm³) under argon was added dropwise a solution of the above tosylate in THF (91 cm³) at 0 °C. After stirring for 10 min, the reaction mixture was warmed to room temperature. After 5 h, the reaction mixture was poured into a saturated solution of sodium potassium tartrate at 0 °C and stirred at room temperature for 1 h. The whole mixture was extracted with Et₂O and the extract was washed with brine, and dried over MgSO₄. The filtrate was concentrated under reduced pressure and the resulting residue was purified by flash chromatography over silica gel with hexane–EtOAc (100 : 0 to 70 : 1) to give compound **24d** (4.9 g, 70%) as a colorless oil: $[\alpha]_D^{27}$ +1.74 (*c* 1.16, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 0.00 (3H, s), 0.03 (3H, s), 0.86–0.89 (18H, m), 1.00–1.05 (1H, m), 1.18–1.26 (1H, m), 1.36–1.42 (2H, m), 1.56–1.60 (1H, m), 1.95–2.00 (1H, m), 3.22 (1H, dd, *J*₁ 8.6, *J*₂ 6.6), 3.37 (1H, dd, *J*₁ 8.6, *J*₂ 7.4), 3.62 (1H, dd, *J*₁ 5.7, *J*₁ 2.3), 4.45–4.52 (2H, m), 7.27–7.34 (5H, m); ¹³C NMR (125 MHz, CDCl₃) δ : –4.3, –3.9, 11.9, 14.4, 15.9, 18.4, 20.7, 26.1 (3C), 35.5, 35.6, 38.3, 72.8, 74.4, 75.4, 127.4, 127.5 (2C), 128.3 (2C), 138.7; HRMS (ESI) calcd for C₂₂H₄₀NaO₂Si (MNa⁺): 387.2690; found: 387.2691.

Methyl (5S,6S,7R,8S,E)-7-(tert-butyltrimethylsilyloxy)-2,6,8-trimethyl-5-(methylthiomethoxy)undec-2-enoate (31). To a stirred solution of **12a** (2.3 g, 6.0 mmol) in DMSO (42.9 cm³) under argon were added Ac₂O (30.5 cm³) and AcOH (5.5 cm³) at room temperature. After stirring overnight, the reaction

mixture was cooled to 0 °C and quenched with saturated aqueous NaHCO₃. The whole mixture was extracted with Et₂O and the extract was washed with H₂O and brine, and dried over MgSO₄. The filtrate was concentrated under reduced pressure and the residue was purified by flash chromatography over silica gel with hexane–EtOAc (30 : 1) to give compound **31** (1.6 g, 59%) as a colorless oil: $[\alpha]_D^{27}$ –75.4 (*c* 0.72, CHCl₃); IR (neat) $\nu_{\max}/\text{cm}^{-1}$: 1716 (C=O); ¹H NMR (500 MHz, CDCl₃) δ : 0.05 (6H, s), 0.85–0.92 (18H, m), 1.15–1.28 (2H, m), 1.33–1.42 (2H, m), 1.62–1.66 (1H, m), 1.85 (3H, d, *J* 1.1), 1.98–2.05 (1H, m), 2.16 (3H, s), 2.26–2.39 (2H, m), 3.47 (1H, dd, *J*₁ 6.9, *J*₂ 2.9), 3.73 (3H, s), 4.00–4.03 (1H, m), 4.53 (1H, d, *J* 11.5), 4.63 (1H, d, *J* 11.5), 6.92–6.95 (1H, m); ¹³C NMR (125 MHz, CDCl₃) δ : –3.7, –3.6, 11.4, 12.8, 14.0, 14.1, 14.3, 18.4, 20.9, 26.2 (3C), 29.1, 36.4, 36.6, 39.0, 51.6, 73.0, 75.9, 77.2, 128.4, 140.3, 168.5; HRMS (ESI) calcd for C₂₃H₄₆NaO₄SSi (MNa⁺): 469.2778; found: 469.2779.

(2R,3S)-3-Methyl-1-oxo-1-(2-oxo-2-phenylethoxy)pentan-2-yl (5S,6S,7R,8S,E)-7-(tert-butyltrimethylsilyloxy)-2,6,8-trimethyl-5-(methylthiomethoxy)undec-2-enoate (32). To a stirred solution of **31** (1.14 g, 2.6 mmol) in MeOH (17 cm³) and THF (17 cm³) was added 1 N LiOH (17 cm³) at 0 °C. The reaction mixture was warmed to 30 °C and stirred overnight. The mixture was concentrated under reduced pressure and EtOAc and 1 N HCl were added to the residue. The whole mixture was extracted with EtOAc and the extract was washed with brine, and dried over MgSO₄. The filtrate was concentrated under reduced pressure and the residue was filtered through a short pad of silica gel with hexane–EtOAc (3 : 1) to give **10**, which was used without further purification. To a stirred solution of acid **10** in CH₂Cl₂ (12.8 cm³) were added MNBA (1.32 g, 3.8 mmol), DMAP (935.0 mg, 7.7 mmol) and **11** (959.0 mg, 3.8 mmol) at room temperature. After stirring overnight, the mixture was quenched with 1 N HCl. The whole mixture was extracted with CH₂Cl₂ and the extract was washed with brine, and dried over MgSO₄. The filtrate was concentrated under reduced pressure and the residue was purified by flash chromatography over silica gel with hexane–EtOAc (10 : 1) to give compound **32** (1.48 g, 87%) as a colorless oil: $[\alpha]_D^{26}$ –43.5 (*c* 0.89, CHCl₃); IR (neat) $\nu_{\max}/\text{cm}^{-1}$: 1710 (C=O); ¹H NMR (500 MHz, CDCl₃) δ : 0.05 (3H, s), 0.07 (3H, s), 0.86–0.91 (18H, m), 0.98 (3H, t, *J* 7.4), 1.15 (3H, d, *J* 6.9), 1.18–1.28 (2H, m), 1.34–1.47 (3H, m), 1.52–1.58 (1H, m), 1.62–1.64 (1H, m), 1.89 (3H, s), 1.99–2.03 (1H, m), 2.11 (3H, s), 2.19–2.25 (1H, m), 2.34–2.37 (2H, m), 3.47 (1H, dd, *J*₁ 7.4, *J*₂ 2.9), 4.01–4.04 (1H, m), 4.52 (1H, d, *J* 11.5), 4.61 (1H, d, *J* 11.5), 5.19 (1H, d, *J* 3.4), 5.25 (1H, d, *J* 16.6), 5.55 (1H, d, *J* 16.6), 7.04–7.07 (1H, m), 7.49 (2H, t, *J* 7.7), 7.60–7.63 (1H, m), 7.89–7.91 (2H, m); ¹³C NMR (125 MHz, CDCl₃) δ : –3.6, –3.5, 11.3, 11.8, 12.7, 14.1, 14.2 (2C), 14.3, 18.4, 20.9, 26.2 (3C), 26.3, 29.4, 36.4, 36.6, 36.9, 39.2, 66.2, 73.0, 74.6, 76.1, 77.2, 127.7 (2C), 128.2, 128.9 (2C), 133.9, 134.1, 141.4, 167.4, 169.7, 191.6; HRMS (ESI) calcd for C₃₆H₆₀NaO₇SSi (MNa⁺): 687.3721; found: 687.3720.

(2R,3S)-3-Methyl-1-oxo-1-(2-oxo-2-phenylethoxy)pentan-2-yl (5S,6R,7R,8S,E)-7-hydroxy-2,6,8-trimethyl-5-(methylthiomethoxy)undec-2-enoate (7). To a stirred solution of **32** (80.7 mg,

0.12 mmol) in THF (0.80 cm³) and pyridine (0.20 cm³) was added HF-pyridine (0.50 cm³) at 0 °C. The reaction mixture was warmed to room temperature and stirred overnight. The reaction mixture was poured into saturated aqueous NaHCO₃ at 0 °C. The whole mixture was extracted with EtOAc, and the extract was washed with brine and 1 N HCl, and dried over MgSO₄. The filtrate was concentrated under reduced pressure and the residue was purified by flash chromatography over silica gel with hexane–EtOAc (6:1) to give compound **7** (49.2 mg, 74%) as a colorless oil: [α]_D²⁵ –5.29 (*c* 1.08, CHCl₃); IR (neat) ν_{max} /cm^{–1}: 3526 (OH), 1708 (C=O); ¹H NMR (500 MHz, CDCl₃) δ : 0.83–0.85 (6H, m), 0.89–0.91 (3H, m), 0.98 (3H, t, *J* 7.4), 1.15 (3H, d, *J* 6.9), 1.24–1.37 (4H, m), 1.38–1.46 (1H, m), 1.50–1.59 (1H, m), 1.61–1.64 (1H, m), 1.90 (3H, s), 1.92–1.99 (1H, m), 2.15–2.16 (4H, m), 2.19–2.26 (1H, m), 2.37–2.49 (2H, m), 3.38–3.41 (1H, m), 4.08–4.12 (1H, m), 4.64 (2H, s), 5.22 (1H, d, *J* 2.9), 5.26 (1H, d, *J* 16.6), 5.55 (1H, d, *J* 16.6), 7.03–7.06 (1H, m), 7.49 (2H, t, *J* 7.7), 7.60–7.63 (1H, m), 7.89–7.91 (2H, m); ¹³C NMR (125 MHz, CDCl₃) δ : 11.4, 11.7 (2C), 12.6, 14.2 (3C), 20.5, 26.3, 29.6, 34.4, 36.7, 36.9, 38.5, 66.2, 73.5, 74.6, 76.2, 78.3, 127.7 (2C), 128.4, 128.9 (2C), 133.9, 134.1, 140.7, 167.4, 169.7, 191.6; HRMS (ESI) calcd for C₃₀H₄₆NaO₇S (MNa⁺): 573.2856; found: 573.2855.

(2R,3S)-3-Methyl-1-oxo-1-(2-oxo-2-phenylethoxy)pentan-2-yl (5S,6S,7R,8S,E)-2,6,8-trimethyl-7-[(N-methyl-L-alanyl)oxy]-5-(methylthiomethoxy)undec-2-enoate (33). Fmoc-MeAla-Cl was synthesised by using the identical procedure reported previously.²⁶ To a stirred solution of Fmoc-MeAla-OH (227.7 mg, 0.70 mmol) in CH₂Cl₂ (3.9 cm³) were added DMF (0.0054 cm³, 0.070 mmol) and SOCl₂ (0.508 cm³, 7.0 mmol) at room temperature. After stirring for 1 h, the mixture was concentrated under reduced pressure to give Fmoc-MeAla-Cl, which was used without further purification. To a stirred solution of **7** (152.6 mg, 0.28 mmol) and the above Fmoc-MeAla-Cl in 1,2-dichloroethane (2.8 cm³) was added *i*-Pr₂NEt (0.244 cm³, 1.40 mmol) at room temperature. The reaction mixture was warmed to 40 °C and stirred for 14 h. The mixture was cooled to room temperature and quenched with saturated aqueous NH₄Cl. The whole mixture was extracted with CH₂Cl₂ and the extract was washed with brine, and dried over MgSO₄. The filtrate was concentrated under reduced pressure and the residue was filtered through a short pad of silica gel with hexane–EtOAc (9:1 to 3:1) to give crude Fmoc-protected amine, which was used without further purification. To a stirred solution of the above protected amine in MeCN (7.0 cm³) was added Et₂NH (2.3 cm³) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 1.5 h. The mixture was concentrated under reduced pressure and the residue was purified by flash chromatography over silica gel with hexane–EtOAc (3:1 to 1:2) to give compound **33** (94.9 mg, 54%) as a yellow oil: [α]_D²⁷ –55.4 (*c* 0.79, CHCl₃); IR (neat) ν_{max} /cm^{–1}: 1712 (C=O); ¹H NMR (500 MHz, CD₃CN) δ : 0.78 (3H, t, *J* 7.2), 0.81–0.84 (6H, m), 0.86 (3H, t, *J* 7.4), 0.99 (3H, d, *J* 6.9), 1.02–1.08 (1H, m), 1.09–1.14 (1H, m), 1.16 (3H, d, *J* 7.1), 1.23–1.34 (3H, m), 1.39–1.47 (1H, m), 1.69–1.77 (4H, m), 1.95 (3H, s), 2.02–2.08 (1H, m), 2.13–2.17 (1H, m), 2.19–2.27 (4H,

m), 2.32–2.36 (1H, m), 3.13 (1H, q, *J* 7.1), 3.63 (1H, dt, *J*₁ 10.3, *J*₂ 2.6), 4.44 (1H, d, *J* 11.5), 4.55 (1H, d, *J* 11.5), 4.79 (1H, dd, *J*₁ 10.3, *J*₂ 2.3), 5.05 (1H, d, *J* 3.4), 5.30 (1H, d, *J* 16.6), 5.42 (1H, d, *J* 16.6), 6.78–6.81 (1H, m), 7.46 (2H, t, *J* 8.0), 7.57–7.61 (1H, m), 7.85–7.87 (2H, m); ¹³C NMR (125 MHz, CD₃CN) δ 10.3, 12.0, 12.8, 13.1, 14.1, 14.4, 14.6, 18.7, 20.9, 26.8, 29.6, 34.4, 34.5, 36.7, 37.0, 37.7, 59.1, 67.7, 73.5, 75.3, 76.1, 78.3, 128.7 (2C), 129.0, 129.8 (2C), 134.9, 135.0, 142.4, 167.9, 170.5, 174.9, 193.2; HRMS (FAB) calcd for C₃₄H₅₄NO₈S (MH⁺): 636.3565; found: 636.3569.

Linear peptides (6a,b). To a stirred solution of **33** (59.5 mg, 0.094 mmol), peptide **9** (185.2 mg) and HOAt (38.4 mg, 0.28 mmol) in CH₂Cl₂ (3.1 cm³) was added EDCI-HCl (54.1 mg, 0.28 mmol) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 24 h. The mixture was quenched with saturated aqueous NaHCO₃. The whole mixture was extracted with CH₂Cl₂ and the extract was washed with saturated aqueous NH₄Cl, and dried over MgSO₄. The filtrate was concentrated under reduced pressure and the residue was purified by flash chromatography over silica gel with hexane–EtOAc (1:1 to 2:3) to give peptide **34** as a 1.4:1 diastereomixture, which was used without further purification. To a stirred solution of **34** in AcOH/EtOAc/H₂O (60:35:5, 4.3 cm³) was added Zn (92.2 mg, 1.4 mmol) at room temperature. After stirring for 8 h, the reaction mixture was filtered through Celite, and 1 N HCl was added to the filtrate. The whole mixture was extracted with EtOAc and the extract was washed with brine, and dried over MgSO₄. After the filtrate was concentrated under reduced pressure, AcOH was removed by azeotropic distillation with toluene to give the corresponding carboxylic acid, which was used without further purification. To a stirred solution of the above acid in MeCN (2.4 cm³) was added Et₂NH (0.80 cm³) at 0 °C. The reaction mixture was warmed to room temperature and stirred for 1.5 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by reverse-phase preparative HPLC (59% CH₃CN in 0.1% TFA solution) to give linear peptides **6a** (29.6 mg, 30% from **33**) and **6b** (24.0 mg, 24% from **33**) as a colorless powder.

6a: [α]_D²⁷ –46.8 (*c* 0.89, CHCl₃); IR (neat) ν_{max} /cm^{–1}: 1645 (C=O); ¹H NMR (500 MHz, CD₃CN, 1:1 mixture of rotamers) δ : 0.77 (1.5H, d, *J* 7.0), 0.81–0.91 (18H, m), 0.96 (1.5H, d, *J* 3.1), 0.97 (1.5H, d, *J* 3.1), 1.06–1.22 (4.5H, m), 1.26–1.33 (3H, m), 1.37 (3H, d, *J* 7.3), 1.41–1.53 (2H, m), 1.74–1.84 (5H, m), 1.96–2.01 (1H, m), 2.07 (1.5H, s), 2.08 (1.5H, s), 2.20–2.38 (3H, m), 2.75–2.86 (4.5H, m), 3.00–3.12 (6.5H, m), 3.53 (0.5H, d, *J* 16.4), 3.70–3.71 (1H, m), 4.00 (0.5H, d, *J* 18.0), 4.05–4.09 (0.5H, m), 4.17 (0.5H, d, *J* 18.0), 4.24 (0.5H, d, *J* 16.4), 4.31–4.36 (0.5H, m), 4.48–4.50 (0.5H, m), 4.53 (0.5H, d, *J* 5.0), 4.55 (0.5H, d, *J* 5.0), 4.62 (0.5H, d, *J* 5.0), 4.64 (0.5H, d, *J* 5.0), 4.73–4.76 (0.5H, m), 4.87–4.89 (1H, m), 4.95 (0.5H, d, *J* 3.4), 4.96 (0.5H, d, *J* 3.4), 5.19 (0.5H, q, *J* 7.3), 5.24 (0.5H, q, *J* 7.3), 5.43–5.46 (0.5H, m), 5.63 (0.5H, dd, *J*₁ 9.9, *J*₂ 5.7), 6.82–6.89 (1H, m), 7.15–7.28 (6H, m), 7.64 (2H, br s); ¹³C NMR (125 MHz, CD₃CN) δ : 10.2 (2C), 11.1, 11.3, 11.9 (2C), 12.7 (2C), 13.0, 13.1, 14.2 (2C), 14.3 (2C), 14.8 (3C), 14.9, 15.5, 15.7, 16.0,

16.1, 20.8 (2C), 24.9, 25.1, 26.8 (2C), 29.3, 29.4, 30.5, 31.5, 32.5 (2C), 34.5, 34.6, 35.4, 35.6, 35.7, 36.8 (2C), 37.0 (3C), 37.2, 37.3 (2C), 37.7, 48.0, 48.6, 52.0, 52.3, 53.5 (2C), 53.7, 55.1, 55.3, 56.0, 73.6 (2C), 75.4, 75.6, 76.5 (2C), 78.9 (2C), 127.4, 127.7, 128.9, 129.0, 129.1 (2C), 129.2 (2C), 130.2 (2C), 130.3 (2C), 137.5, 137.8, 142.4 (2C), 168.3, 168.5, 168.9, 169.5, 170.0, 170.4, 171.2, 171.7, 172.2, 172.3, 172.5 (2C), 173.4, 174.0; HRMS (ESI) calcd for $C_{48}H_{80}N_5O_{11}S$ (MH^+): 934.5570; found: 934.5567.

6b: $[\alpha]_D^{28}$ -23.5 (c 1.00, $CHCl_3$); IR (neat) ν_{max}/cm^{-1} : 1648 ($C=O$); 1H NMR (500 MHz, CD_3CN , 3 : 3 : 3 : 1 mixture of rotamers) δ : 0.74 (0.9H, d, J 6.9), 0.78–0.98 (21.9H, m), 1.05 (1.2H, d, J 6.9), 1.08–1.51 (11H, m), 1.75–1.90 (5H, m), 1.97–2.02 (1H, m), 2.05–2.06 (2.7H, m), 2.09 (0.3H, s), 2.19–2.45 (3H, m), 2.72 (0.3H, s), 2.81–2.86 (4.8H, m), 2.89–2.91 (2H, m), 2.93 (0.3H, s), 2.95 (0.3H, s), 3.00–3.09 (1.8H, m), 3.12–3.18 (1.5H, m), 3.43 (0.1H, d, J 16.1), 3.55–3.56 (0.1H, m), 3.61–3.76 (1.6H, m), 4.09–4.16 (0.6H, m), 4.25–4.36 (1.3H, m), 4.45–4.48 (0.4H, m), 4.52–4.64 (1.9H, m), 4.70–4.73 (0.3H, m), 4.79–5.00 (3H, m), 5.08–5.12 (0.7H, m), 5.26 (0.3H, dd, J_1 9.3, J_2 6.0), 5.33 (0.3H, dd, J_1 11.1, J_2 4.4), 5.46 (0.3H, dd, J_1 11.1, J_2 4.8), 5.52 (0.1H, dd, J_1 9.5, J_2 6.4), 6.84–6.91 (1H, m), 6.97 (0.3H, d, J 9.2), 7.07–7.26 (5H, m), 7.42 (0.3H, d, J 7.3), 7.69 (0.4H, d, J 6.7), 8.11 (2H, br s); ^{13}C NMR (125 MHz, CD_3CN) δ : 10.3 (3C), 10.6, 12.0 (2C), 12.2 (2C), 12.8, 12.9, 13.2 (3C), 13.7, 14.2 (2C), 14.4 (2C), 14.6 (2C), 14.7, 14.8, 14.9 (2C), 15.1, 15.2, 15.9 (2C), 16.1 (2C), 16.2, 16.3, 20.8, 20.9, 26.8 (2C), 26.9 (2C), 27.0 (2C), 27.4, 29.4, 29.5 (2C), 29.6, 30.4, 30.5, 30.6, 31.1, 31.9, 32.6, 32.7, 33.6, 34.5, 34.6, 34.7, 35.2, 35.3, 35.4, 35.5, 35.6, 35.9, 36.5, 36.8, 37.0 (4C), 37.1, 37.2, 37.4 (2C), 38.1, 38.4, 48.0 (2C), 48.6 (2C), 52.5, 52.6, 53.0, 53.2, 54.0, 54.3 (2C), 54.7, 54.8, 55.0, 56.4, 57.1, 58.1, 73.5, 75.3 (2C), 75.6 (2C), 75.9, 76.1 (2C), 78.6, 79.0, 79.6, 79.7, 127.5 (2C), 127.6, 129.1 (3C), 129.2 (3C), 129.3, 130.2 (2C), 130.3 (3C), 130.4 (2C), 137.5, 137.8, 138.1, 138.3, 141.4, 141.5, 141.9, 142.2, 167.9, 168.1, 168.2, 168.3, 168.7, 169.6, 170.1, 170.2, 170.3 (2C), 170.8, 171.2 (2C), 171.3, 171.4, 171.8, 172.0, 172.2 (2C), 172.5, 173.4, 174.4, 174.7; HRMS (ESI) calcd for $C_{48}H_{80}N_5O_{11}S$ (MH^+): 934.5570; found: 934.5580.

Odoamide (5a). To a stirred solution of **6a** (17.8 mg, 0.017 mmol), HOAt (11.6 mg, 0.085 mmol) and collidine (0.067 cm^3 , 0.51 mmol) in DMF (17.0 cm^3) was added HATU (64.6 mg, 0.17 mmol) at room temperature. After stirring for 5 h, the reaction mixture was concentrated under reduced pressure, and EtOAc and 1 N HCl were added to the residue. The whole mixture was extracted with EtOAc and the extract was washed with brine and saturated aqueous $NaHCO_3$, and dried over $MgSO_4$. The filtrate was concentrated under reduced pressure and the residue was purified by flash chromatography over silica gel with hexane–EtOAc (1 : 1 to 0 : 1) to give the corresponding cyclic peptide. To a stirred solution of the above cyclic peptide in THF/ H_2O (4 : 1, 0.566 cm^3) were added 2,6-lutidine (0.0394 cm^3 , 0.34 mmol) and $AgNO_3$ (115.5 mg, 0.68 mmol) at room temperature. The reaction mixture was warmed to 70 °C and stirred for 4 h. The mixture was filtered through Celite, and 1 N HCl was added to the filtrate. The

whole mixture was extracted with EtOAc and the extract was washed with H_2O , saturated aqueous $NaHCO_3$ and brine, and dried over $MgSO_4$. The filtrate was concentrated under reduced pressure and the residue was purified by reverse-phase preparative HPLC (72% CH_3CN in H_2O) to give odoamide (**5a**) (12.4 mg, 85%) as a colorless powder: $[\alpha]_D^{28}$ -15.8 (c 1.14, CH_3OH); IR (neat) ν_{max}/cm^{-1} : 3305 (OH), 1645 ($C=O$); 1H NMR (500 MHz, CD_3OD) δ : 0.83–0.96 (21H, m), 1.04–1.12 (4H, m), 1.19–1.26 (1H, m), 1.29–1.40 (4H, m), 1.42 (3H, d, J 6.9), 1.45–1.55 (1H, m), 1.57–1.67 (1H, m), 1.78–1.87 (3H, m), 1.90 (3H, s), 2.01–2.04 (1H, m), 2.12–2.16 (1H, m), 2.20–2.28 (1H, m), 2.85–2.95 (4H, m), 3.01–3.06 (4H, m), 3.30 (3H, s), 3.56 (1H, d, J 18.3), 3.74–3.76 (1H, m), 3.94 (1H, q, J 6.9), 4.19 (1H, d, J 18.3), 4.49 (1H, q, J 6.9), 4.86–4.89 (2H, m), 5.05 (1H, d, J 6.3), 5.45 (1H, dd, J_1 10.3, J_2 5.2), 7.12–7.20 (5H, m), 7.31–7.32 (1H, m); ^{13}C NMR (125 MHz, CD_3OD) δ : 10.0, 11.7, 12.0, 12.1, 13.1, 13.8, 14.5, 14.6, 15.6, 16.0, 21.6, 24.7, 27.4, 30.5 (2C), 35.8, 35.9, 36.6, 37.6, 37.8, 38.5, 39.4, 41.3, 46.4, 52.6, 54.7, 55.0, 60.3, 71.5, 77.6, 79.2, 127.4, 128.6, 129.1 (2C), 130.6 (2C), 138.4, 146.8, 170.4, 171.3, 172.5, 172.7, 172.8, 173.0, 174.9; HRMS (ESI) calcd for $C_{46}H_{73}N_5NaO_{10}$ (MNa^+): 878.5250; found: 878.5254.

Growth inhibition assay

A549 cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Sigma) supplemented with 10% (v/v) fetal bovine serum at 37 °C in a 5% CO_2 -incubator. Growth inhibition assays using A549 cells were performed in 96-well plates (BD Falcon). A549 cells were seeded at 500 cells per well in 0.050 cm^3 of culture media, respectively, and were cultured for 6 h. Chemical compounds in DMSO were diluted 250-fold with the culture medium in advance. Following the addition of 0.040 cm^3 of the fresh culture medium to the cell cultures, 0.030 cm^3 of the chemical diluents were also added. The final volume of DMSO in the medium was equal to 0.1% (v/v). The cells under chemical treatment were incubated for further 72 h. The wells in the plates were washed twice with the cultured medium without phenol-red. After 1 h incubation with 0.100 cm^3 of the medium, the cell culture in each well was supplemented with 0.020 cm^3 of the MTS reagent (Promega), followed by incubation for additional 40 min. Absorbance at 490 nm of each well was measured using a Wallac 1420 ARVO SX multilabel counter (Perkin Elmer). Three experiments were performed per condition and the average of inhibition rates in each condition was evaluated to determine IC_{50} values using the GraphPad Prism software.

Acknowledgements

This work was supported by Grants-in-Aid for Scientific Research from JSPS, Japan (24659004 and 15J05499); the Platform for Drug Discovery, Informatics, and Structural Life Science from MEXT, Japan; and the Takeda Science Foundation. M. K. is grateful for JSPS Research Fellowships for Young Scientists.

References

- For reviews, see: (a) Y. Hamada and T. Shioiri, *Chem. Rev.*, 2005, **105**, 4441–4482; (b) S. Sivanathan and J. Scherckenbeck, *Molecules*, 2014, **19**, 12368–12420.
- For reviews, see: (a) J. Chatterjee, C. Gilon, A. Hoffman and H. Kessler, *Acc. Chem. Res.*, 2008, **41**, 1331–1342; (b) J. Chatterjee, F. Rechenmacher and H. Kessler, *Angew. Chem., Int. Ed.*, 2013, **52**, 254–269.
- (a) W. Huang, R. G. Ren, H. Q. Dong, B. G. Wei and G. Q. Lin, *J. Org. Chem.*, 2013, **78**, 10747–10762; (b) J. Tulla-Puche, S. Auriemma, C. Falciani and F. Albericio, *J. Med. Chem.*, 2013, **56**, 5587–5600; (c) M. Pelay-Gimeno, A. Meli, J. Tulla-Puche and F. Albericio, *J. Med. Chem.*, 2013, **56**, 9780–9788; (d) R. Nabika, S. Oishi, R. Misu, H. Ohno and N. Fujii, *Bioorg. Med. Chem.*, 2014, **22**, 6156–6162; (e) W. He, H.-B. Qui, Y.-J. Chen, J. Xi and Z.-J. Yao, *Tetrahedron Lett.*, 2014, **55**, 6109–6112; (f) R. Nabika, T. L. Suyama, A. M. Hau, R. Misu, H. Ohno, J. E. Ishmael, K. L. McPhail, S. Oishi and N. Fujii, *Bioorg. Med. Chem. Lett.*, 2015, **25**, 302–306; (g) G. Yao, Z. Pan, C. Wu, W. Wang, L. Fang and W. Su, *J. Am. Chem. Soc.*, 2015, **137**, 13488–13491.
- (a) K. Suenaga, T. Mutou, T. Shibata, T. Itoh, H. Kigoshi and K. Yamada, *Tetrahedron Lett.*, 1996, **37**, 6771–6774; (b) K. Suenaga, T. Mutou, T. Shibata, T. Itoh, T. Fujita, N. Takada, K. Hayamizu, M. Takagi, T. Irifune, H. Kigoshi and K. Yamada, *Tetrahedron*, 2004, **60**, 8509–8527.
- B. Han, H. Gross, D. E. Goeger, S. L. Mooberry and W. H. Gerwick, *J. Nat. Prod.*, 2006, **69**, 572–575.
- Y. Nakao, W. Y. Yoshida, Y. Takada, J. Kimura, L. Yang, S. L. Mooberry and P. J. Scheuer, *J. Nat. Prod.*, 2004, **67**, 1332–1340.
- A. Tripathi, J. Puddick, M. R. Prinsep, M. Rottmann and L. T. Tan, *J. Nat. Prod.*, 2010, **73**, 1810–1814.
- A. Tripathi, J. Puddick, M. R. Prinsep, M. Rottmann, K. P. Chan, D. Y. Chen and L. T. Tan, *Phytochemistry*, 2011, **72**, 2369–2375.
- P. G. Williams, W. Y. Yoshida, M. K. Quon, R. E. Moore and V. J. Paul, *J. Nat. Prod.*, 2003, **66**, 1545–1549.
- P. Marfey, *Carlsberg Res. Commun.*, 1984, **49**, 591–596.
- (a) T. Mutou, K. Suenaga, T. Fujita, T. Itoh, N. Takada, K. Hayamizu, H. Kigoshi and K. Yamada, *Synlett*, 1997, 199–201; (b) Y. Takada, E. Mori, M. Umehara, Y. Nakao and J. Kimura, *Tetrahedron Lett.*, 2007, **48**, 7653–7656; (c) Y. Takada, M. Umehara, Y. Nakao and J. Kimura, *Tetrahedron Lett.*, 2008, **49**, 1163–1165; (d) L. Dai, B. Chen, H. Lei, Z. Wang, Y. Liu, Z. Xu and T. Ye, *Chem. Commun.*, 2012, **48**, 8697–8699.
- The isolation and structural assignment of odoamide were reported in our previous article, see: K. Sueyoshi, M. Kaneda, S. Sumimoto, S. Oishi, N. Fujii, K. Suenaga and T. Teruya, *Tetrahedron*, 2016, **72**, 5472–5478.
- I. Ohtani, T. Kusumi, Y. Kashman and H. Kakisawa, *J. Am. Chem. Soc.*, 1991, **113**, 4092–4096.
- E. Marcucci, J. Tulla-Puche and F. Albericio, *Org. Lett.*, 2012, **14**, 612–615.
- (a) G. C. Stelakatos, A. Paganou and L. Zervas, *J. Chem. Soc. C*, 1966, 1191–1199; (b) T. Takahashi, H. Nagamiya, T. Doi, P. G. Griffiths and A. M. Bray, *J. Comb. Chem.*, 2003, **5**, 414–428.
- T. Kawabata, Y. Kimura, Y. Ito, S. Terashima, A. Sasaki and M. Sunagawa, *Tetrahedron*, 1988, **44**, 2149–2165.
- (a) D. A. Evans, J. Bartroli and T. L. Shih, *J. Am. Chem. Soc.*, 1981, **103**, 2127–2129; (b) D. A. Evans, J. V. Nelson, E. Vogel and T. R. Taber, *J. Am. Chem. Soc.*, 1981, **103**, 3099–3111.
- Alcohol **20c** was synthesised from *ent*-**13** according to a similar process in a previous report, see: A. Zampella, M. Sorgente and M. V. D'Auria, *Tetrahedron: Asymmetry*, 2002, **13**, 681–685.
- (a) T. Mukaiyama, K. Banno and K. Narasaka, *J. Am. Chem. Soc.*, 1974, **96**, 7503–7509; (b) D. A. Evans, M. J. Dart, J. L. Duffy and M. G. Yang, *J. Am. Chem. Soc.*, 1996, **118**, 4322–4343.
- (a) D. W. Cameron, M. G. Looney and J. A. Pattermann, *Tetrahedron Lett.*, 1995, **36**, 7555–7558; (b) G. T. Kim, M. Wenz, J. I. Park, J. Hasseroth and K. D. Janda, *Bioorg. Med. Chem.*, 2002, **10**, 1249–1262.
- Two hydroxy group configurations in **12c** and **12d** were determined by the NMR analysis of the corresponding acetones.
- (5*R*)-Hydroxy ester **26a** is the substrate for the synthesis of (5*S*)-hydroxy ester **12a** (see the ESI†).¹²
- S. D. Rychnovsky, B. Rogers and G. Yang, *J. Org. Chem.*, 1993, **58**, 3511–3515.
- P. M. Pojer and S. J. Angyal, *Aust. J. Chem.*, 1978, **31**, 1031–1040.
- (a) I. Shiina, R. Ibuka and M. Kubota, *Chem. Lett.*, 2002, **31**, 286–287; (b) I. Shiina, M. Kubota, H. Oshiumi and M. Hashizume, *J. Org. Chem.*, 2004, **69**, 1822–1830.
- L. A. Carpino, B. J. Cohen, K. E. Stephens, Jr., S. Y. Sadat-Aalae, J. H. Tien and D. C. Langridge, *J. Org. Chem.*, 1986, **51**, 3732–3734.
- Among several conditions investigated for coupling of peptide **9**, EDCI-HOAt provided the desired compound **6a** in higher chemical yield; however, significant epimerization at the C-terminal L-Ile occurred.
- J. D. White and M. Kawasaki, *J. Org. Chem.*, 1992, **57**, 5292–5300.